Mycobutin (Rifabutin)

Rifabutin acts on mycobacterial infections and is used in specific clinical scenarios.

• Mycobacterium avium complex (MAC) infection in HIV‑positive patients: used for prevention and treatment of MAC disease, reducing bacterial burden and related complications.
• Active tuberculosis caused by susceptible Mycobacterium tuberculosis strains: incorporated into combination regimens to eradicate infection and prevent resistance development.
• Disseminated MAC infection in immunocompromised individuals: employed to control systemic disease and improve clinical outcomes.

• Rifabutin inhibits the bacterial DNA‑dependent RNA polymerase by binding to the β‑subunit of the enzyme. This blockade suppresses transcription of essential genes, leading to cessation of protein synthesis and bacterial replication. The selective inhibition of mycobacterial RNA polymerase results in bacteriostatic activity against susceptible Mycobacterium species, including M. tuberculosis and M. avium complex. By targeting a critical step in gene expression, rifabutin limits bacterial growth without directly killing host cells.

Rifabutin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea
• Vomiting
• Abdominal pain or discomfort
• Diarrhea
• Rash or pruritus
• Headache

Serious or Rare Side Effects

• Neutropenia or leukopenia
• Hepatotoxicity (elevated liver enzymes, hepatitis)
• Severe skin reactions such as Stevens‑Johnson syndrome
• Visual disturbances or uveitis
• Fever with chills
• Acute renal impairment

When prescribing rifabutin, clinicians should observe several safety considerations to minimize risk.

• Assess liver function: obtain baseline hepatic enzyme tests before initiating therapy.
• Monitor blood counts: perform periodic complete blood counts to detect neutropenia or anemia.
• Evaluate hypersensitivity: avoid use in patients with known allergy to rifamycins.
• Review antiretroviral regimen: adjust concomitant HIV drugs due to potential pharmacokinetic interactions.
• Consider pregnancy and lactation: prescribe only if benefit outweighs potential risk, as safety data are limited.
• Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Rifabutin interacts with several drug classes, influencing its plasma concentration and therapeutic effect.

Major Interactions (Avoid)

• Protease inhibitors (e.g., ritonavir): markedly increase rifabutin levels, raising toxicity risk.
• Macrolide antibiotics (e.g., clarithromycin, azithromycin): elevate rifabutin concentrations, potentially causing severe adverse effects.
• Strong CYP3A inducers (e.g., efavirenz, nevirapine): reduce rifabutin exposure, compromising efficacy.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin): may enhance anticoagulant effect, requiring INR monitoring.
• Oral contraceptives: rifabutin may decrease hormonal efficacy, advise additional contraceptive measures.
• Anticonvulsants (phenytoin, carbamazepine): can lower rifabutin levels, possibly necessitating dose adjustment.